FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

107 letters match. Newest first.

  1. Bliv Wellness LLC dba Bliv

    FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

    Medium
  2. BluefitMD

    FDA warned BluefitMD that its website falsely labels compounded semaglutide and tirzepatide as its own and as FDA-approved.

    Low
  3. Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics

    FDA warned Deluxe IV and Aesthetics over misleading website claims for compounded semaglutide and tirzepatide, including implying FDA approval.

    Low
  4. Aspen Aesthetics dba Fifty 410

    FDA warns Fifty 410 over misleading website claims for compounded semaglutide and tirzepatide, including implied compounding and 'clinically proven' claims.

    Low
  5. FitRX, LLC dba FitRx

    FitRx's website misbranded compounded semaglutide and tirzepatide with false and misleading claims, FDA says.

    Medium
  6. Genesis Health International Inc. dba Genesis

    FDA warns Genesis over misleading website claims for compounded semaglutide and tirzepatide.

    Low
  7. Get.Fit.Medical, LLC dba Get.Fit.Medical

    FDA warned Get.Fit.Medical that its website sold compounded sildenafil, tadalafil, semaglutide and tirzepatide with false 'generic' claims.

    High risk
  8. FWD Care, Inc. dba FWD

    FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.

    Medium
  9. Expert Aesthetics

    FDA warned Expert Aesthetics over website claims that its compounded semaglutide and tirzepatide are generic Ozempic and Mounjaro.

    Low
  10. Healthy Living Clinic

    FDA warned Healthy Living Clinic that its website misbrands compounded semaglutide by comparing it to Wegovy, Ozempic, and Rybelsus.

    Low
  11. Hims & Hers Health, Inc. dba Hers

    FDA warned Hims & Hers (Hers) that its website misleads consumers about compounded semaglutide by implying it is the same as approved Ozempic and Wegovy.

    Medium
  12. Amazing Meds

    FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.

    High risk
  13. FitRX, LLC dba Zealthy

    FDA warns Zealthy over website claims that compounded semaglutide is the same as Wegovy and Ozempic.

    Medium
  14. Lean Dreams LLC dba LeanDreams

    FDA warned LeanDreams over website claims that compounded semaglutide and tirzepatide match FDA-approved Ozempic, Wegovy, Mounjaro and Zepbound.

    Low
  15. ybycmeds

    FDA warns ybycmeds over website claims that compounded semaglutide and tirzepatide are similar to approved brand-name drugs.

    Medium
  16. iVisitDoc, Inc. dba iVisitDoc

    FDA warns iVisitDoc over website claims that compounded semaglutide is equivalent to Wegovy and Ozempic, calling the drugs misbranded.

    Medium
  17. Try Nova

    FDA warned Try Nova that its website’s compounded semaglutide claim "Same active ingredient as Wegovy & Ozempic" is false or misleading.

    Low
  18. Lovely Meds, Inc. dba Lovely Meds

    FDA cited Lovely Meds for misleading website claims that compounded semaglutide and tirzepatide are the same as FDA-approved drugs.

    Low
  19. The HCG Institute

    FDA warns The HCG Institute over misleading claims for compounded semaglutide sold online.

    High risk
  20. Vitals RX

    FDA warned telehealth seller Vitals RX that its website falsely implies compounded semaglutide and tirzepatide are the approved drug Ozempic.

    Medium
  21. Tuyo Health, Inc. dba Tuyo Health

    FDA warns Tuyo Health over misleading claims for compounded semaglutide and tirzepatide sold online.

    Medium
  22. Las Villas Health Care LLC dba Villas Health

    FDA warned Villas Health over website claims for compounded semaglutide and sildenafil, calling the drugs misbranded and unapproved.

    High risk
  23. Lyfe Rx

    Lyfe Rx offered compounded semaglutide and tirzepatide online with false 'clinically proven weight loss' claims, FDA says.

    Low
  24. JulyMD

    FDA warned JulyMD that its website sold compounded semaglutide with misleading claims comparing it to Wegovy and Ozempic.

    High risk
  25. Slendid

    FDA warned Slendid that its website sells compounded semaglutide and tirzepatide with a false "clinically proven" claim, making the drugs misbranded.

    Medium
  26. Sprout Health Partners LLC dba Sprout Health

    FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.

    Low
  27. Master Pharmaceuticals Group

    FDA warned Master Pharmaceuticals Group that its website sold compounded semaglutide and tirzepatide with false or misleading claims.

    High risk
  28. TRYM Health, Inc. dba TRYM Health

    FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.

    Medium
  29. HealBerry

    FDA warned HealBerry that claiming compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' misbrands its drugs.

    Medium
  30. Reset IV, LLC dba Reset IV

    FDA warned Reset IV that its website misbrands compounded semaglutide and tirzepatide by claiming they are the same as FDA-approved drugs.

    Medium
  31. inspire.clinic

    FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.

    Low
  32. Bioverse, Inc. dba Bioverse

    FDA warned Bioverse that its website made false or misleading claims for compounded semaglutide and tirzepatide drugs.

    Low
  33. SimpleRx

    FDA warned SimpleRx that its website falsely implied compounded semaglutide and tirzepatide were Ozempic or Zepbound.

    High risk
  34. Elevate Your Wellness LLC, dba Elevated

    FDA warned Elevated that its website offered compounded semaglutide and tirzepatide with misleading claims they match FDA-approved drugs.

    Low
  35. Cosmo Medical Spa dba Cosmo Med Spa

    FDA warned Cosmo Med Spa over its website selling compounded semaglutide with claims implying it is FDA-approved Ozempic.

    Medium
  36. EvoLife Wellness

    FDA warned EvoLife Wellness that its website wrongly calls compounded semaglutide and tirzepatide "FDA-Approved," making the drugs misbranded.

    Medium
  37. Nuvo Life Health Inc. dba Nuvo Life Health

    FDA warned Nuvo Life Health that its website sold compounded semaglutide and tirzepatide with misleading claims comparing them to FDA-approved drugs.

    Medium
  38. SemaBio

    FDA warned SemaBio that its website sold compounded semaglutide and called it 'generic semaglutide,' a false or misleading claim.

    Low
  39. directmeds.com, Inc. dba DirectMeds

    FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.

    High risk
  40. Hims & Hers Health, Inc. dba Hims

    FDA warns Hims that compounded semaglutide website claims are false or misleading and misbrand the drugs.

    High risk
  41. MedClub by Dr. Jenn

    FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.

    High risk
  42. Mane & Steel, LLC. dba Mane & Steel

    FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.

    Low
  43. Lumimeds

    FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.

    High risk
  44. ASN-LABS

    ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.

    High risk
  45. Body Good Studio

    FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.

    High risk
  46. Canada Med Stop

    Canada Med Stop marketed compounded semaglutide online as FDA-approved and generic, making the drugs misbranded.

    Medium
  47. All American Wellness

    FDA warned telehealth seller All American Wellness that its website wrongly compares compounded semaglutide and tirzepatide to Ozempic and Mounjaro.

    Low
  48. Intimate Rose

    FDA warned Intimate Rose that its website sells compounded semaglutide and tirzepatide with misleading claims that they match approved drugs.

    High risk
  49. Invigorate Med Spa

    Invigorate Med Spa's website claimed compounded semaglutide and tirzepatide were Wegovy and Mounjaro, making them misbranded.

    Low
  50. Dr. Gater’s Weight Loss & Wellness

    Dr. Gater’s Weight Loss & Wellness marketed compounded semaglutide and tirzepatide with false or misleading FDA-approval and generic-Ozempic claims.

    Medium